IFRX – InflaRx N.V.
InflaRx N.V.IFRX
$0.83Name : InflaRx N.V.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $56,230,096.00
EPSttm : -0.84
InflaRx N.V.
$0.83
2.21%$0.019Float Short %
1.74
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
-0.01
EPS Last/This Y
0.25
EPS This/Next Y
0.03
Price
0.85
Target Price
4.34
Analyst Recom
1.38
Performance Q
-29.83
Relative Volume
0.68
Beta
1.32
Ticker: IFRX
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-05-07 | IFRX | 1.48 | 0.00 | 0.00 | 1573 |
| 2025-05-08 | IFRX | 1.6 | 0.00 | 0.00 | 1683 |
| 2025-05-09 | IFRX | 1.6 | 0.00 | 0.00 | 1708 |
| 2025-05-12 | IFRX | 1.67 | 0.00 | 0.00 | 1725 |
| 2025-05-13 | IFRX | 1.78 | 0.00 | 0.00 | 1799 |
| 2025-05-14 | IFRX | 1.84 | 0.00 | 0.00 | 1800 |
| 2025-05-15 | IFRX | 1.77 | 0.00 | 0.00 | 1802 |
| 2025-05-16 | IFRX | 1.66 | 0.00 | 0.00 | 2524 |
| 2025-05-19 | IFRX | 1.773 | 0.00 | 0.00 | 2926 |
| 2025-05-20 | IFRX | 1.74 | 0.00 | 0.00 | 3585 |
| 2025-05-21 | IFRX | 1.66 | 0.00 | 0.00 | 3586 |
| 2025-05-22 | IFRX | 1.82 | 0.00 | 0.00 | 3587 |
| 2025-05-23 | IFRX | 1.85 | 0.00 | 0.00 | 4137 |
| 2025-05-27 | IFRX | 1.82 | 0.00 | 0.00 | 4321 |
| 2025-05-28 | IFRX | 0.7285 | 0.00 | 0.00 | 4366 |
| 2025-05-29 | IFRX | 0.8699 | 0.00 | 0.00 | 4505 |
| 2025-05-30 | IFRX | 0.813 | 0.00 | 0.00 | 4622 |
| 2025-06-02 | IFRX | 0.7987 | 0.00 | 0.00 | 4621 |
| 2025-06-03 | IFRX | 0.85 | 0.00 | 0.00 | 4627 |
| 2025-06-04 | IFRX | 0.8401 | 0.00 | 0.00 | 4627 |
| 2025-06-05 | IFRX | 0.831 | 0.00 | 0.00 | 4628 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-05-07 | IFRX | 1.49 | -5.9 | - | -0.66 |
| 2025-05-08 | IFRX | 1.55 | -5.9 | - | -0.66 |
| 2025-05-09 | IFRX | 1.60 | -5.9 | - | -0.68 |
| 2025-05-12 | IFRX | 1.67 | -5.9 | - | -0.68 |
| 2025-05-13 | IFRX | 1.79 | 31.3 | - | -0.68 |
| 2025-05-14 | IFRX | 1.85 | 31.3 | - | -0.68 |
| 2025-05-15 | IFRX | 1.76 | 31.3 | - | -0.68 |
| 2025-05-16 | IFRX | 1.66 | 31.3 | - | -0.68 |
| 2025-05-19 | IFRX | 1.77 | 13.9 | - | -0.72 |
| 2025-05-20 | IFRX | 1.77 | 13.9 | - | -0.72 |
| 2025-05-21 | IFRX | 1.69 | 13.9 | - | -0.72 |
| 2025-05-22 | IFRX | 1.81 | 13.9 | - | -0.72 |
| 2025-05-23 | IFRX | 1.85 | 13.9 | - | -0.72 |
| 2025-05-27 | IFRX | 1.82 | 13.9 | - | -0.72 |
| 2025-05-28 | IFRX | 0.73 | 13.9 | - | -0.72 |
| 2025-05-29 | IFRX | 0.87 | 13.9 | - | -0.72 |
| 2025-05-30 | IFRX | 0.80 | 13.9 | - | -0.72 |
| 2025-06-02 | IFRX | 0.80 | 13.9 | - | -0.63 |
| 2025-06-03 | IFRX | 0.88 | 15.3 | - | -0.63 |
| 2025-06-04 | IFRX | 0.85 | 15.3 | - | -0.63 |
| 2025-06-05 | IFRX | 0.85 | 15.3 | - | -0.63 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-05-07 | IFRX | 0.00 | 1.76 | 1.62 |
| 2025-05-08 | IFRX | 0.00 | 1.76 | 1.62 |
| 2025-05-09 | IFRX | 0.00 | 1.76 | 1.62 |
| 2025-05-12 | IFRX | 0.00 | 1.76 | 1.98 |
| 2025-05-13 | IFRX | 0.00 | 1.76 | 1.98 |
| 2025-05-14 | IFRX | 0.00 | 1.76 | 1.98 |
| 2025-05-15 | IFRX | 0.00 | 1.76 | 1.98 |
| 2025-05-16 | IFRX | 0.00 | 1.76 | 1.98 |
| 2025-05-19 | IFRX | 0.00 | 1.95 | 1.98 |
| 2025-05-20 | IFRX | 0.00 | 1.95 | 1.98 |
| 2025-05-21 | IFRX | 0.00 | 1.95 | 1.98 |
| 2025-05-22 | IFRX | 0.00 | 1.95 | 1.98 |
| 2025-05-23 | IFRX | 0.00 | 1.95 | 1.98 |
| 2025-05-27 | IFRX | 0.00 | 70.59 | 1.98 |
| 2025-05-28 | IFRX | 0.00 | 70.59 | 1.74 |
| 2025-05-29 | IFRX | 0.00 | 70.59 | 1.74 |
| 2025-05-30 | IFRX | 0.00 | 70.59 | 1.74 |
| 2025-06-02 | IFRX | 0.00 | 70.59 | 1.74 |
| 2025-06-03 | IFRX | 0.00 | 70.59 | 1.74 |
| 2025-06-04 | IFRX | 0.00 | 70.59 | 1.74 |
| 2025-06-05 | IFRX | 0.00 | 70.59 | 1.74 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.14
Avg. EPS Est. Current Quarter
-0.2
Avg. EPS Est. Next Quarter
-0.15
Insider Transactions
Institutional Transactions
70.59
Beta
1.32
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
25
Growth Score
31
Sentiment Score
48
Actual DrawDown %
89.7
Max Drawdown 5-Year %
-91.1
Target Price
4.34
P/E
Forward P/E
PEG
P/S
316.63
P/B
0.76
P/Free Cash Flow
EPS
-1.05
Average EPS Est. Cur. Y
-0.63
EPS Next Y. (Est.)
-0.6
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-33446.81
Relative Volume
0.68
Return on Equity vs Sector %
-87.5
Return on Equity vs Industry %
-69.6
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.02
EBIT Estimation
InflaRx N.V.Sector: Healthcare
Industry: Biotechnology
Employees: 74
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.
stock quote shares IFRX – InflaRx N.V. Stock Price stock today
news today IFRX – InflaRx N.V. stock forecast ,stock prediction 2023 2024 2025
marketwatch IFRX – InflaRx N.V. yahoo finance google finance
stock history IFRX – InflaRx N.V. invest stock market
stock prices IFRX premarket after hours
ticker IFRX fair value insiders trading